
We're witnessing the early stages of a paradigm shift, as artificial intelligence is beginning to impact virtually every aspect of healthcare, from research to patient care. And there's much, much more to come. This week, Dr. Brad Willingham, the Director of MS Research at Shepherd Center in Atlanta, joins me to discuss how AI will impact MS patient care. We'll also share the encouraging results from a Phase 2 open-label extension study for Fenebrutinib, an investigational disease-modifying therapy. We'll tell you about study results that show exercise interventions that follow physical activity guidelines for MS can have a significant impact on MS-related depression. And we're sharing the results of a study that illustrate what can happen when you delay starting a disease-modifying therapy. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: How AI will impact MS patient care :22 Fenebrutinib shows positive results after one-year extension study 1:33 MS-related depression can be significantly eased through exercise intervention that follows physical activity guidelines for MS 3:36 What happens when you delay starting disease-modifying therapy? 8:46 Dr. Brad Willingham discusses how artificial intelligence is impacting all aspects of healthcare 14:29 Share this episode 33:18 Have you downloaded the free RealTalk MS app? 33:38 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/413 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Become an MS Activist https://nationalmssociety.org/advocacy STUDY: Safety and Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (FENopta): A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase 2 Trial and Open-Label Extension https://thelancet.com/journals/laneur/article/PIIS1474-4422(25)00174-7/abstract?rss=yes STUDY: Effects of Meeting Exercise Guidelines on Depression and Anxiety in Multiple Sclerosis: A Systematic Review and Meta-Analysis https://tandfonline.com/doi/full/10.1080/09593985.2025.2518261 Exercise and Physical Activity Recommendations for ALL People with MS https://nationalmssociety.org/news-and-magazine/news/exercise-and-physical-activity-recommend STUDY: Delayed Access and Adherence are Real-World Challenges That Compromise Effectiveness of Natalizumab in Multiple Sclerosis https://sciencedirect.com/science/article/abs/pii/S2211034825003694 Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Devices https://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 413 Guest: Dr. Brad Willingham Privacy Policy
From "RealTalk MS"
Comments
Add comment Feedback